LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mobile Real Time PCR Device Enables COVID-19 Detection in Near-Patient Setting

By LabMedica International staff writers
Posted on 01 Aug 2022
Print article
Image: Liberty16 Pro (Photo courtesy of Ubiquitome)
Image: Liberty16 Pro (Photo courtesy of Ubiquitome)

A mobile real time PCR device can expand COVID-19 testing capacity and enable pathogen detection with a multiplex assay at high speed, in addition to offering simplicity of use.

Ubiquitome Limited (Auckland, New Zealand) has unveiled its new COVID PCR testing tool named Liberty16 Pro that allows workplaces of up to 500 employees to conduct COVID-testing efficiently with a single, real time PCR device. Surveillance testing at onsite locations can give better early warning, as well as potentially being more cost effective than rapid antigen tests. Liberty16 Pro is an advanced version of Ubiquitome’s Liberty16 mobile real time PCR device which has FDA emergency use authorization for use with the Yale School of Public Health SalivaDirect SARS-CoV-2 assay for diagnostic purposes at certain designated CLIA laboratories.

The Liberty16 mobile PCR system had allowed workplaces to instigate surveillance - checking patients pre-admission, monitoring staff, splitting teams into shifts, and keeping vital supply chain services running. After training by Ubiquitome, many companies and organizations set up dedicated rooms on site and interpret sample results with ease through Ubiquitome's proprietary mobile phone app. Ubiquitome has now developed an advanced version of Liberty16 to expand testing capacity and enable pathogen detection with a multiplex assay and even greater speed - while retaining the existing simplicity of use. The Liberty16 and Liberty16 Pro are research use only devices, not for diagnostic purposes.

"The need for diagnostics that advance clinical care and public health has never been greater with the mutation of Omicron variants picking up speed," said Dr. Paul Pickering, Ubiquitome's CEO. "Developments in the Liberty16 Pro potentially expand testing capacity without sacrificing the assay's detection sensitivity, while further reducing test consumable costs and retaining the unique features which are best fit to a near-patient setting."

Related Links:
Ubiquitome Limited 

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Sekisui Diagnostics UK Ltd.